Ignite Creation Date:
2025-12-24 @ 7:49 PM
Ignite Modification Date:
2025-12-29 @ 5:05 PM
Study NCT ID:
NCT01221103
Status:
UNKNOWN
Last Update Posted:
2011-09-13
First Post:
2010-10-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Sponsor:
Southern Europe New Drug Organization
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-04
Start Date Type:
None
Primary Completion Date:
2012-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2012-06
Completion Date Type:
ESTIMATED
First Submit Date:
2010-10-13
First Submit QC Date:
None
Study First Post Date:
2010-10-14
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-09-12
Last Update Post Date:
2011-09-13
Last Update Post Date Type:
ESTIMATED